Precigen Target of Unusually Large Options Trading (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) was the target of unusually large options trading on Thursday. Traders acquired 11,343 call options on the company. This is an increase of approximately 3,908% compared to the typical daily volume of 283 call options.

Precigen Stock Up 11.1 %

PGEN stock opened at $1.20 on Friday. The stock has a market cap of $351.44 million, a price-to-earnings ratio of -2.18 and a beta of 1.65. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $1.93. The business has a 50 day moving average price of $0.85 and a 200 day moving average price of $1.09.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Precigen in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $7.00.

Institutional Trading of Precigen

Several institutional investors have recently modified their holdings of the stock. Traphagen Investment Advisors LLC acquired a new stake in Precigen during the 3rd quarter worth $29,000. Stifel Financial Corp increased its position in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 15,680 shares during the period. SG Americas Securities LLC lifted its position in Precigen by 44.2% during the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 13,823 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 25,681 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares during the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.